Brought to you by 
Seres Health brings in $65mm via Series D
03 Feb 2015
Executive Summary
Just one month after closing a $48mm Series C round, Seres Health Inc. (microbiome therapeutics) raised $65mm in its Series D financing to Nestle Health Science. The proceeds will help move its lead compound SER109 for preventing the recurrence of Clostridium difficile infection into Phase III and to advance other pipeline candidates. Nestle Health’s CEO joins Seres Health’s board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seres Health brings in $65mm via Series D
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice